Guidelines for the management of patients with rosacea are summarized.
Insurance coverage for topical treatments for rosacea vs melasma are investigated.
Migraine may be more common in people with rosacea.
The safety and efficacy of intradermal microinjections of tranexamic acid for erythematotelangiectatic rosacea was evaluated.
Efficacy and tolerability for a 15% AzA cream in addressing inflammatory rosacea was assessed.
Ivermectin cream, 1% is indicated for the treatment of inflammatory lesions of rosacea.
The etiology of rosacea, with an emphasis on the role of UV radiation and exposome, and to review the importance of nonpharmacologic strategies focusing on photoprotection, is described.
Patients with ocular rosacea who underwent combined treatments reported less discomfort.
The efficacy and tolerability of daily cream containing N-butanoyl-l-glutathione (GSH-C4), beta-glycyrrhetinic, and azelaic acid for treatment in patients with mild to moderate rosacea was evaluated.
Vyne Therapeutics announced the availability of Zilxi (minocycline) topical foam 1.5% for the treatment of inflammatory lesions of rosacea in adults.